等待開盤 06-25 09:30:00 美东时间
+1.155
+4.86%
MasterCraft Boat Holdings director Callum C. Macgregor files initial beneficial ownership statement MasterCraft Boat Holdings director Callum C. Macgregor filed an initial Form 3 on May 26 for a May 15 reporting date. Disclaimer: This news brief was created by Public Technologies (PUBT) using genera
05-27 08:40
MasterCraft Boat Holdings director Stephen E. Lewis files initial beneficial ownership statement MasterCraft Boat Holdings director Stephen E. Lewis reported ownership of 1,345 common shares in an initial SEC filing dated May 15, 2026. Disclaimer: This news brief was created by Public Technologies (
05-27 08:39
MasterCraft Boat to pay $425,000 in fees to end Delaware shareholder suit MasterCraft Boat Holdings agreed to pay USD 425,000 in attorneys’ fees and expenses to resolve a Delaware Chancery Court stockholder suit that challenged provisions in a Feb. 5, 2026 stockholders agreement. The plaintiff sough
05-22 20:31
Marine Products ( ($MPX) ) has shared an update. Marine Products Corporation he...
05-13 05:56
MasterCraft Boat Holdings ( ($MCFT) ) has provided an update. On May 12, 2026, ...
05-13 05:33
Mastercraft Boat Holdings (($MCFT)) has held its Q3 earnings call. Read on for ...
05-08 10:26
MasterCraft Boat Hldgs (NASDAQ:MCFT) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.36 by 25 percent. This is a 50 percent increase over earnings of $0.30 per share from
05-07 19:34
Charles "Chip" Gerlach has been appointed as General Manager of Crest and Balise Pontoons, subsidiaries of MasterCraft Boat Holdings. Gerlach will oversee product innovation, dealer partnerships, and operational performance. With extensive experience in the marine industry, he is well-positioned to drive growth and innovation for the brands. Mike O’Connell, the previous General Manager, will transition to Senior Vice President of Operational Exce...
05-06 15:00
An update from MasterCraft Boat Holdings ( ($MCFT) ) is now available. MasterCr...
05-02 06:18
今日重点评级关注:Ascendiant Capital:维持NRX Pharmaceuticals"买入"评级,目标价从48美元升至49美元;Chardan Capital:维持Intellia Therapeutics"买入"评级,目标价从27美元升至30美元
04-28 10:07